Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2021 | Combination treatment for migraine

Andrew Blumenfeld, MD, The Neurology Center of Southern California, Carlsbad, CA, discusses the importance of considering combination treatment for migraine and suggests that up to now, the migraine field has focused on monotherapeutic approaches. However, for certain patients, monotherapy is unlikely to be sufficient to control the disease since migraine is a multi-mechanistic disorder. Dr Blumenfeld believes that the future lies in building synergistic combinations to treat acutely and preventively. This interview took place during the European Academy of Neurology 2021 congress.

Disclosures

Dr Blumenfeld reports the following disclosures:
Advisory Board: Allergan, Abbvie, Aeon, Alder, Amgen, Axsome, Biohaven, Impel, Lundbeck, Lilly, Novartis, Revance, Teva, Theranica, Zoscano
Speaker fees: Allergan, Abbvie, Amgen, Biohaven, Lundbeck, Lilly, Teva
Consultant: Allergan, Abbvie, Alder, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Teva, Theranica
Grant support: Allergan, Amgen
Contributing author: Allergan, Abbvie, Amgen, Novartis, Teva, Lilly, Biohaven